Ancera
Branford
About Ancera
Ancera is focused on engineering simple, practical, rapid, and cost-effective diagnostics products that can cause a revolutionary change to the quality of service provided to the end-user. The company's PIPER platform, enables near real-time, rapid detection and quantification of microbial threats across all points in the food production process, from farm-to-consumer. Their flagship product is a rapid, labor- and label-free cell sorter and immunoassay. It is capable of cell sorting, concentration, manipulation, and detection of clinically significant samples (>1cc) in <10 minutes. Their device has high sensitivity and specificity and does not require any sample preparation, handling, or incubation. Ancera offers an integrated solution capable of label-free sorting, microscopy, enumeration, assaying, and recovery of cells directly from complex food sources. They monitor and assess microbial data to provide meaningful operational and food security outcomes for the food industry.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2016)
- Website: ancera.com
- Phone: 2038192322
Industries & Categories
Biotechnology, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/ancera-131499 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.